Please assess the completion status of the following clinical trial:

Trial Title: PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Confirmed diagnosis of invasive BCC~* Progression of disease on hedgehog inhibitor (HHI) therapy or intolerance of prior HHI therapy~* At least 1 measurable lesion~* ≥18 years of age~* Hepatic function, renal function, bone marrow function in defined lab-value-ranges~* Anticipated life expectancy \>12 weeks~* Consent to provide archived tumor biopsy material (all patients)~* Group 2: consent to undergo research biopsies~* Group 2: must not be a candidate for radiation therapy or surgery~* Comply with study procedures and site visits~* Sign Subject Information Sheet and Informed Consent Form~Key Exclusion Criteria:~* Ongoing or recent significant autoimmune disease~* Prior treatment with specific pathway-blockers (PD-1/PD-L1)~* Prior treatment with immune-modulating agents within 28 days before cemiplimab~* Untreated brain metastasis that may be considered active~* Immunosuppressive corticosteroid doses (\>10mg prednisone) within 28 days prior to treatment with cemiplimab~* Active infections requiring therapy, including HIV, hepatitis~* Pneumonitis within the last 5 years~* Cancer treatment other than radiation therapy, including investigational or standard of care, within 30 days prior to treatment with cemiplimab~* Documented allergic reactions or similar to antibody treatments~* Concurrent malignancies other than BCC, other than those with negligible risk of metastases or death~* Any acute or chronic psychiatric problems~* Having received a solid organ transplantation~* Inability to undergo contrast radiological assessments~* Breastfeeding, pregnant, women of childbearing potential not using contraception~Note: Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1- metastatic BCC (Type: EXPERIMENTAL): Administration of cemiplimab in accordance with protocol dosing regimen
- Group 2 - unresectable locally advanced BCC (Type: EXPERIMENTAL): Administration of cemiplimab in accordance with protocol dosing regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).